Biologic Treatment Options for Retinal Neovascularization in Behçet's Disease (Q39430605)

11 September 2017

Biologic Treatment Options for Retinal Neovascularization in Behçet's Disease (English)

1 reference

11 September 2017

0 references

1 reference

5

Petros P Sfikakis

1 reference

11 September 2017

Nikos N Markomichelakis

1

1 reference

11 September 2017

Evaggelia K Aissopou

2

1 reference

11 September 2017

Stelios Maselos

3

1 reference

11 September 2017

Ilknur Tugal-Tutkun

4

1 reference

11 September 2017

12 July 2017

1 reference

Ocular Immunology and Inflammation

11 September 2017

1 reference

11 September 2017

1-7

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1332228

11 September 2017

1 reference

Immunopathology of the noninfectious posterior and intermediate uveitides

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1332228

Uveitis in Behçet disease: an analysis of 880 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1332228

Phenotype and functional changes of Vgamma9/Vdelta2 T lymphocytes in Behçet's disease and the effect of infliximab on Vgamma9/Vdelta2 T cell expansion, activation and cytotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1332228

Role of IL-22- and TNF-α-producing Th22 cells in uveitis patients with Behcet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1332228

Effect of infliximab on sight-threatening panuveitis in Behçet's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1332228

Infliximab in the treatment of refractory posterior uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1332228

Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1332228

A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet's disease: a comparative 4-week study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1332228

Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1332228

Safety and efficacy of infliximab therapy in active behcet's uveitis: an open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1332228

Multicenter study of infliximab for refractory uveoretinitis in Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1332228

Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet's disease: a multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1332228

Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1332228

Clinical course of patients with Behçet's uveitis following discontinuation of infliximab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1332228

Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1332228

Current concepts in the etiology and treatment of Behçet disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1332228

Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1332228

Adalimumab for the treatment of Behçet's disease: experience in 19 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1332228

Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1332228

Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1332228

Neovascularisation associated with posterior uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1332228

Corticosteroid therapy for optic disc neovascularization secondary to chronic uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1332228

Retinal and disc neovascularization in Behçet's disease and efficacy of laser photocoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1332228

Neovascularization of the optic disc in Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1332228

The use of interferon alpha in Behçet disease: review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1332228

Regression of optic disc neovascularization in patients with Behçet's uveoretinitis after infliximab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1332228

Clinical Experience of Interferon Alfa-2a Treatment for Refractory Uveitis in Behçet's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1332228

Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1332228

Complete regression of retinal neovascularization after therapy with interferon alfa in Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1332228

Anti-TNF- therapy in patients with refractory uveitis due to Behcet's disease: a 1-year follow-up study of 124 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F09273948.2017.1332228

10.1080/09273948.2017.1332228

21 January 2018

Identifiers

DOI

1 reference

11 September 2017

1 reference